Phase II study of cetrorelix, a luteinizing hormone-releasing hormone antagonist in patients with platinum-resistant ovarian cancer.

Verschraegen CF, Westphalen S, Hu W, Loyer E, Kudelka A, Völker P, Kavanagh J, Steger M, Schulz KD, Emons G

Gynecologic oncology1 Sept 2003Cited by 33 (Europe PMC)

PMID13678723DOI10.1016/s0090-8258(03)00408-6PepBankPUB-13678723

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. 10 results from people.

01HumanNon-randomized trialEfficacy outcome
In platinum-resistant ovarian cancer, three cetrorelix-treated patients had partial remissions lasting 9, 16, and 17 weeks.
In plain wordsThree cetrorelix-treated patients with platinum-resistant ovarian cancer had partial remissions lasting 9, 16, and 17 weeks.
Peptide
Cetrorelix
Outcome
Not applicablePartial remission
Study
n = 17
Outcome group
Tumor growth · Cancer
Studied dose
10 mg every day · subcutaneousAs given in this study (human).
Measurements
Patients with partial remission
3 patients
Platinum-resistant ovarian cancer, cetrorelix 10 mg daily
Partial remission duration
9 weeks
First responder
Partial remission duration
16 weeks
Second responder
Partial remission duration
17 weeks
Third responder
Source sentences
Summary
Three patients had partial remissions lasting 9, 16, and 17 weeks.
2 context sentences(design, population, supporting numbers)
Summary · context
Eligible patients with ovarian or mullerian carcinoma resistant to platinum chemotherapy received cetrorelix 10 mg subcutaneously every day.
Summary · context
Seventeen patients were treated.
Report a problemFND-1367872301
02HumanNon-randomized trialSafety outcome
In platinum-resistant ovarian cancer, one cetrorelix-treated patient had a grade 4 anaphylactoid reaction controlled with cortisol and cimetidine.
In plain wordsOne cetrorelix-treated patient had a grade 4 anaphylactoid reaction controlled with cortisol and cimetidine.
Peptide
Cetrorelix
Outcome
Not applicableGrade 4 anaphylactoid reaction
Study
n = 17
Outcome group
Adverse events · Immune and inflammation
Studied dose
10 mg every day · subcutaneousAs given in this study (human).
Measurements
Patients with grade 4 anaphylactoid reaction
1 patients
Cetrorelix 10 mg daily
Source sentences
Summary
Toxicities effects included grade 4 anaphylactoid reaction (one patient) controlled by cortisol and cimetidine,
2 context sentences(design, population, supporting numbers)
Summary · context
Eligible patients with ovarian or mullerian carcinoma resistant to platinum chemotherapy received cetrorelix 10 mg subcutaneously every day.
Summary · context
Seventeen patients were treated.
Report a problemFND-1367872302
03HumanNon-randomized trialSafety outcome
In platinum-resistant ovarian cancer, two cetrorelix-treated patients had grade 2 histamine reactions.
In plain wordsTwo cetrorelix-treated patients had grade 2 histamine reactions.
Peptide
Cetrorelix
Outcome
Not applicableGrade 2 histamine reaction
Study
n = 17
Outcome group
Adverse events · Immune and inflammation
Studied dose
10 mg every day · subcutaneousAs given in this study (human).
Measurements
Patients with grade 2 histamine reaction
2 patients
Cetrorelix 10 mg daily
Source sentences
Summary
grade 2 histamine reaction (two patients),
2 context sentences(design, population, supporting numbers)
Summary · context
Eligible patients with ovarian or mullerian carcinoma resistant to platinum chemotherapy received cetrorelix 10 mg subcutaneously every day.
Summary · context
Seventeen patients were treated.
Report a problemFND-1367872303
04HumanNon-randomized trialSafety outcome
In platinum-resistant ovarian cancer, one cetrorelix-treated patient had grade 2 arthralgia.
In plain wordsOne cetrorelix-treated patient had grade 2 joint pain.
Peptide
Cetrorelix
Outcome
Not applicableGrade 2 arthralgia
Study
n = 17
Outcome group
Adverse events · Musculoskeletal
Studied dose
10 mg every day · subcutaneousAs given in this study (human).
Measurements
Patients with grade 2 arthralgia
1 patients
Cetrorelix 10 mg daily
Source sentences
Summary
grade 2 arthralgia (one patient)
2 context sentences(design, population, supporting numbers)
Summary · context
Eligible patients with ovarian or mullerian carcinoma resistant to platinum chemotherapy received cetrorelix 10 mg subcutaneously every day.
Summary · context
Seventeen patients were treated.
Report a problemFND-1367872304
05HumanNon-randomized trialSafety outcome
In platinum-resistant ovarian cancer, two cetrorelix-treated patients had a 20% cholesterol increase without requiring specific treatment.
In plain wordsTwo cetrorelix-treated patients had a 20% cholesterol increase without requiring specific treatment.
Peptide
Cetrorelix
Outcome
IncreaseCholesterol increase
Study
n = 17
Outcome group
Lipids · Metabolic and weight
Studied dose
10 mg every day · subcutaneousAs given in this study (human).
Measurements
Cholesterol increase
20%
Cetrorelix 10 mg daily
Patients with cholesterol increase
2 patients
Cetrorelix 10 mg daily
Source sentences
Summary
20% cholesterol increase (two patients, who did not require specific treatment),
2 context sentences(design, population, supporting numbers)
Summary · context
Eligible patients with ovarian or mullerian carcinoma resistant to platinum chemotherapy received cetrorelix 10 mg subcutaneously every day.
Summary · context
Seventeen patients were treated.
Report a problemFND-1367872305
06HumanNon-randomized trialSafety outcome
In platinum-resistant ovarian cancer, cetrorelix toxicities included minor hot flushes.
In plain wordsCetrorelix toxicities included minor hot flushes in patients with platinum-resistant ovarian cancer.
Peptide
Cetrorelix
Outcome
Not applicableHot flushes
Study
n = 17
Outcome group
Adverse events · Endocrine and hormones
Studied dose
10 mg every day · subcutaneousAs given in this study (human).
Source sentences
Summary
minor hot flushes, headache, and local skin reaction at the injection site.
2 context sentences(design, population, supporting numbers)
Summary · context
Eligible patients with ovarian or mullerian carcinoma resistant to platinum chemotherapy received cetrorelix 10 mg subcutaneously every day.
Summary · context
Seventeen patients were treated.
Report a problemFND-1367872306
07HumanNon-randomized trialSafety outcome
In platinum-resistant ovarian cancer, cetrorelix toxicities included headache.
In plain wordsCetrorelix toxicities included headache in patients with platinum-resistant ovarian cancer.
Peptide
Cetrorelix
Outcome
Not applicableHeadache
Study
n = 17
Outcome group
Adverse events · Nervous system and cognition
Studied dose
10 mg every day · subcutaneousAs given in this study (human).
Source sentences
Summary
minor hot flushes, headache, and local skin reaction at the injection site.
2 context sentences(design, population, supporting numbers)
Summary · context
Eligible patients with ovarian or mullerian carcinoma resistant to platinum chemotherapy received cetrorelix 10 mg subcutaneously every day.
Summary · context
Seventeen patients were treated.
Report a problemFND-1367872307
08HumanNon-randomized trialSafety outcome
In platinum-resistant ovarian cancer, cetrorelix toxicities included local skin reactions at the injection site.
In plain wordsCetrorelix toxicities included local skin reactions at the injection site.
Peptide
Cetrorelix
Outcome
Not applicableInjection-site skin reaction
Study
n = 17
Outcome group
Adverse events · Skin and wound
Studied dose
10 mg every day · subcutaneousAs given in this study (human).
Source sentences
Summary
minor hot flushes, headache, and local skin reaction at the injection site.
2 context sentences(design, population, supporting numbers)
Summary · context
Eligible patients with ovarian or mullerian carcinoma resistant to platinum chemotherapy received cetrorelix 10 mg subcutaneously every day.
Summary · context
Seventeen patients were treated.
Report a problemFND-1367872308
09HumanNon-randomized trialEfficacy outcome
In platinum-resistant ovarian cancer, the cetrorelix-treated patient without the LHRH receptor did not respond.
In plain wordsThe cetrorelix-treated patient without the LHRH receptor did not respond.
Peptide
Cetrorelix
Outcome
Not applicableResponse without LHRH receptor
Study
n = 1
Outcome group
Tumor growth · Cancer
Studied dose
10 mg every day · subcutaneousAs given in this study (human).
Source sentences
Summary
The patient who had no receptor did not respond.
2 context sentences(design, population, supporting numbers)
Summary · context
Eligible patients with ovarian or mullerian carcinoma resistant to platinum chemotherapy received cetrorelix 10 mg subcutaneously every day.
Summary · context
Seventeen patients were treated.
Report a problemFND-1367872310
10HumanNon-randomized trialMechanism
In platinum-resistant ovarian cancer, two patients who responded to cetrorelix were LHRH receptor positive.
In plain wordsTwo patients who responded to cetrorelix were LHRH receptor positive.
Peptide
Cetrorelix
Outcome
Not applicableLHRH receptor positivity among responders
Study
n: not reported in source
Outcome group
Receptor activity and mechanism · Cancer
Studied dose
10 mg every day · subcutaneousAs given in this study (human).
Measurements
Responding patients who were LHRH receptor positive
2 patients
Cetrorelix 10 mg daily
Source sentences
Summary
Two responding patients were LHRH receptor positive.
2 context sentences(design, population, supporting numbers)
Summary · context
Eligible patients with ovarian or mullerian carcinoma resistant to platinum chemotherapy received cetrorelix 10 mg subcutaneously every day.
Summary · context
Seventeen patients were treated.
Report a problemFND-1367872309

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:35 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.